Galapagos NV announced that it has identified the first pre-clinical candidate compound in its osteoarthritis alliance with Servier. The compound inhibits a novel mechanism of action discovered by Galapagos. This achievement triggered an undisclosed milestone payment to Galapagos. In July ... more
To use all functions of this page, please activate cookies in your browser.